CAMP4 secures $100 million in Series B financing

CAMP4 is a diagnostic technology developer in the field of genetic engineering. Its 4-D gene circuit platform, combining epigenomics, computational biology and machine learning functions, can quickly provide solutions, find drug targets, and realize the detection of any disease gene. control. CAMP4 Therapeutics recently secured a $100 million Series B round led by Enavate Sciences, with participation from Gainels, 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, and The Kraft Group.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment